| Status | Study |
| Recruiting |
Study Name: Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine Condition: Acute Lymphoblastic Leukemia Acute Myelogenous Leukemia My Date: 2016-12-01 Interventions: Drug: Bendamustine |
| Recruiting |
Study Name: Myeloproliferative Neoplasms (MPNs) Patient Registry Condition: Primary Myelofibrosis Polycythemia Vera Essential Thromboc Date: 2016-03-24 Interventions: Other: Observational |
| Withdrawn |
Study Name: Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) Condition: Chronic Myelomonocytic Leukemia Juvenile Myelomonocytic Leukemia Date: 2015-09-29 Interventions: Drug: Pacritinib -Patients sho |
| Recruiting |
Study Name: Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) Condition: Myelodysplastic Syndrome Leukemia, Myelomonocytic, Juvenile Date: 2015-04-14 Interventions: Drug: Azacitidine Other Name: Vidaza |
| Recruiting |
Study Name: Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies Condition: Acute Lymphoblastic Leukemia/Lymphoma Myelodysplasia Acute Date: 2015-01-12 |
| Recruiting |
Study Name: Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation Condition: Acute Myelogenous Leukemia Acute Lymphoid Leukemia Date: 2015-01-05 Interventions: Drug: azacitidine 40mg/m2 IV/S |
| Active, not recruiting |
Study Name: Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies Condition: Acute Lymphoblastic Leukaemias (ALL) Acute Myeloid Leukaemias (AML) Date: 2014-12-22 Interventions: Drug: Treosulfan Treosulfan dose per day is to be calculat |
| Recruiting |
Study Name: CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant Condition: Chronic Myeloid Leukemia (CML) Acute Myelogenous Leukemia (AML); Date: 2014-02-11 Interventions: Device: CliniMACS CD34+ Reagent System |
| Active, not recruiting |
Study Name: Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia Condition: Juvenile Myelomonocytic Leukemia Date: 2013-04-02 Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation |
| Recruiting |
Study Name: Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Condition: Accelerated Phase Chronic Myelogenous Leukemia Adult Acute Lymphoblastic Leukemia in Remissi Date: 2013-01-02 Interventions: Drug: Fludarabine phosphate Gi |